Articles

Fear, rejection, and “othering” of people living with epilepsy continues to be a major additional burden, a burden beyond seizures, for many people globally.

The complex interplay between metabolic dysfunction and brain insulin resistance in schizophrenia warrants further investigation as it represents a unique opportunity for both mechanistic inquiry and the development of novel therapeutic strategies that can improve metabolic and cognitive outcomes in this population.

Virtual Reality (VR) technology enables a new form of exposure therapy through the creation of a so-called virtual world, known as “in-virtuo” exposure.

Major Depressive Disorder (MDD) is a highly prevalent psychiatric condition with significant individual and socio-economic burden​. Despite the broad availability of numerous effective therapeutic interventions, up to 30% of patients fail to achieve adequate symptom relief and are classified as having treatment-resistant depression (TRD). TRD represents a significant clinical challenge, affecting approximately 30% of individuals with MDD who fail to respond to at least two adequate antidepressant trials.

This article examines the limitations of current treatments for anxiety disorders and surveys promising new pharmacological approaches such as novel GABAergic agents, psychedelics, and neuropeptide modulators.

This article reviews the shift towards more personalised care by integrating biological and clinical profiles to guide mechanism-based, targeted interventions across psychiatric conditions.